Boehringer Ingelheim will invest $149 million in China for new facilities including an R&D center; Simcere Pharma (????) acquired China rights to a dual-mechanism cancer drug from OSI Pharma; California's stem cell agency will collaborate with China's Ministry of Science and Technology; Shanghai ChemPartner will open a European headquarters office in Denmark; BioTime presented its work on the use of stem cells as a cancer therapy at a conference; China Medical Technologies (????????) received SFDA approval for its Surface Plasmon Resonance (SPR) diagnostic technology; China Medicine Corporation registered its vascular drug in Pakistan; Sinovac Biotech (????????????) was approved to distribute its swine flu vaccine in Mexico; Advanced BioMedical Technologies has completed the clinical trial of its absorbable orthopedic implant screw; Bonovo Orthopedics will distribute surgical procedure products in China for elliquence llc; and China Biologic Products was named to Forbes' 2009 list of "200 Best under a Billion" for Asia. More details...
BioTime, Inc. announced that Dr. David Jin, Chief Medical Officer of BioTime’s newly formed subsidiary, OncoCyte Corporation, will present the keynote address at the Fifth Chinese Congress on Stem Cell Therapy in Beijing. The presentation, which will be delivered Friday, October 23, will discuss OncoCyte’s technology that uses hemangiogenic stem cell technology to target and destroy tumors. More details...
Three life science companies will IPO on Shenzhen’s Growth Enterprise Market (GEM), a new Nasdaq-like exchange; AMDL will spin off its China subsidiary Jade Pharma; BioTime will establish a China subsidiary to market its stem cell products in China; China Biologic Products entered an R&D agreement with the Institute of Blood Transfusion of Chengdu; the Mimotopes China & VPSmart-DDS Biodelivery Centers opened its doors in WuXi to develop peptide products; Jiangsu Yanshen Biological Technology was given SFDA approval for its H1N1 flu vaccine; Hualan Biological Bacterin has struck an H1N1 flu vaccine deal with Julphar of the United Arab Emirates; and Tianyin Pharmaceutical announced solid gains in its 2009 fiscal year. More details...
BioTime, Inc. will establish a China subsidiary, called BioTime Asia, to market the company’s stem cell products in China and throughout Asia. The company will also seek to develop stem cell therapies for a number of diseases, including the use of genetically modified stem cells to treat currently incurable forms of cancer. BioTime has engaged the services of Dr. Lu Daopei, a prominent China hematologist, to manage the clinical trials of its therapeutic stem cell products. More details...
BioTime, Inc. announced that Dr. David Jin, Chief Medical Officer of BioTime’s newly formed subsidiary, OncoCyte Corporation, will present the keynote address at the Fifth Chinese Congress on Stem Cell Therapy in Beijing. The presentation, which will be delivered Friday, October 23, will discuss OncoCyte’s technology that uses hemangiogenic stem cell technology to target and destroy tumors.[More...]
BioTime, Inc. (BTIM), Wataire International, Inc. (WTAR), and Applied DNA Sciences, Inc. (APDN) were among this morning’s top OTC market movers.
BioTime, Inc. (BTIM.OB: 5.62 +24.89%), which develops synthetic plasma expanders and blood volume substitute solutions, saw its shares jump more than 20 percent after announcing that it would present at the 2009 World Stem Cell [...]
BioTime, Inc. (BTIM), China Digital Communication Group (CHID), Savoy Energy Corporation (SNVP), Health Enhancement Products, Inc. (HEPI), and FutureFuel Corporation (FTFL) were among today’s top OTC movers.
BioTime, Inc. (BTIM.OB: 3.16 +23.92%), a biomedical organization engaged in the development of synthetic plasma expanders and blood volume substitute solutions, saw its shares jump more than 10 percent [...]
The accompanying table (click to enlarge) includes 40 companies in the ETF Innovators Global Stem Cell and Regenerative Medicine Index, which represents an expansion of the Emerging Stem Cell Index I have written about previously. The expanded global index includes companies with market caps less than $1B at the index inception with a total market value of $3,814 as of the close[More...]
Get daily news and insights for the advertising, automotive, energy, financial services, food, health care, media, pharmaceutical, retail, technology, and travel industries.
